CVRx

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVRx reports stellar Q4 results, eyes growth opportunities in 2023

CVRx's strong performance in 2022, highlighted by revenue growth and operational advancements, sets a positive trajectory for the company. While challenges persist in European market expansion, the focus on key growth areas and strategic initiatives positions CVRx for continued success in 2023.

CVRx reports stellar Q1 performance, eyes label expansions for growth

CVRx's Q1 2023 showcased robust revenue growth, operational progress, and increased guidance for the full year. While challenges like rising expenses and inventory management exist, the company's focus on profitability, label expansions, and market expansion programs position it well for future success.

CVRx excels in Q2 with robust revenue growth and market expansion

CVRx's strong Q2 performance, revenue growth, and strategic initiatives position the company for future success in the heart failure market.
While facing challenges in clinical trial enrollment and regulatory uncertainties, CVRx's focus on market expansion and pricing optimization presents opportunities for sustained growth.
With a clear roadmap for revenue improvement, cash flow optimization, and market penetration, CVRx is poised to capitalize on the growing demand for its therapies.

CVRx reports robust Q3 performance, raises full-year revenue guidance

CVRx delivered a strong performance in Q3 2023, marked by revenue growth and operational advancements.
While facing challenges like net losses and regulatory uncertainties, the company is well-positioned for future growth.
Opportunities lie in market expansion, revenue growth, and maintaining operational efficiencies for sustained success.

CVRx posts robust Q4 earnings, eyes growth amid leadership transition

CVRx reported strong financial performance in Q4 2023, with significant revenue growth and operational achievements.
The company faces challenges in managing expenses, designing new clinical studies, and balancing growth strategies.
Opportunities lie in expanding market opportunities, engaging stakeholders for new programs, and pursuing aggressive growth strategies.
Guidance for 2024 indicates a positive outlook with revenue projections and strategic focus on growth and operational efficiency.

CVRx reports revenue growth in Q1, focuses on therapy adoption

CVRx's Q1 performance showed revenue growth but faced challenges from disruptions and increased expenses.
Strengthening market development efforts and therapy adoption are key focus areas for CVRx.
Opportunities lie in improving awareness, evidence, and access for Barostim therapy.
Navigating challenges like sales turnover and market dynamics will be crucial for CVRx's growth.

CVRx reports strong revenue growth and strategic leadership enhancements

CVRx's Q2 2024 performance showed revenue growth and strategic leadership enhancements.
While challenges like increased expenses and net losses persist, opportunities for revenue growth exist.
The company's focus on market advocacy and product development positions it for future success.

CVRx reports revenue growth and strategic focus amidst rising expenses

CVRx shows revenue growth and positive therapy outcomes but faces challenges in managing expenses. The company's financial position remains stable with a focus on strategic growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Thursday, June 8, 2023. The Company is scheduled to present at the conference at 9:20 am Central Time (10:20 am Eastern Time). A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com . About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike VallieICR Westwicke443-213-0501 ir@cvrx.com Media Contact: Laura O'NeillFinn Partners402-499-8203 laura.oneill@finnpartners.com

CVRx to Present at the William Blair 43rd Annual Growth Stock Conference

CVRx, Inc. (NASDAQ:CVRX ) Q1 2023 Earnings Conference Call April 27, 2023 5:00 PM ET Company Participants Michael Vallie - Investor Relations Nadim Yared - President and Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Will Plovanic - Canaccord Genuity Alex Nowak - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets Operator Greetings, and welcome to the CVRx Q1 2023 Earnings Call. At this time, all participants are in a listen-only-mode.

CVRx, Inc. (CVRX) Q1 2023 Earnings Call Transcript

CVRx (CVRX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.49 per share a year ago.

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2023.

CVRx Reports First Quarter 2023 Financial and Operating Results

MINNEAPOLIS, April 20, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2023 financial and operating results after market close on Thursday, April 27th, 2023. The Company will host a conference call to review its results at 5:00 p.m. Eastern Time the same day.

CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure (HF) Therapeutics (THT) conference on Tuesday, March 21, 2023. These results are being presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).

Totality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics (THT) conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston. These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).

CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK--(BUSINESS WIRE)---- $CVRX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). CVRx investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cvrx. The investigation concerns whether CVRx violated federal securities laws.

Bronstein, Gewirtz & Grossman, LLC Notifies CVRx, Inc. (CVRX) Investors of Investigation

CVRx Inc (NASDAQ:CVRX) stock is on track for its worst single session ever, down 43.3% to trade at $9.75 at last glance, after news that the medical device company's post-market phase trial of its chronic heart failure therapy, Barostim, did not reach its primary goal.

Medical Device Stock Eyes Worst Day Ever

Shares of CVRx Inc. CVRX, -1.71% tumbled 33.7% in premarket trading Tuesday, putting them on track for a record one-day selloff, after the medical device company said a trial of its BeAT-HF therapy for heart failure did not reach statistical significance on the primary endpoint. The company said the results did contain “clinically meaningful” analyses that favored its Barostim extravascular implantable neuromodulation device, and provided a favorable safety profile.

CVRx stock tumbles after trial for heart failure therapy failed to meet primary endpoing

The trial did not meet its primary endpoint, however, the totality of data supports Barostim's use as an effective treatment for patients with heart failure The trial did not meet its primary endpoint, however, the totality of data supports Barostim's use as an effective treatment for patients with heart failure

CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

CVRx, Inc. (NASDAQ:CVRX ) Q4 2022 Earnings Conference Call January 26, 2023 5:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President and Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Alex Nowak - Craig-Hallum Operator Good day and welcome to the CVRx Q4 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

CVRx, Inc. (CVRX) Q4 2022 Earnings Call Transcript

Fourth Quarter 2022 Revenue of $7.2 million, a 96% Increase Over Prior Year Fourth Quarter 2022 Revenue of $7.2 million, a 96% Increase Over Prior Year

CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter and full year 2022 financial and operating results after market close on Thursday, January 26, 2023. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2022 revenue results, and provided a 2023 business outlook.

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

MINNEAPOLIS, Dec. 28, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The Company is scheduled to present at the conference at 3:45 pm Pacific Time.

CVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --   CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022.

CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

Q3 revenues came in 82% higher YoY to $6.2mm, with the heart failure business growing to $4.9mm for the quarter. Market data is improving, along with more visibility on macro variables and less price volatility in equity markets as a result.

CVRx: Barostim Accelerating, Upside Targets Forming (Technical Analysis)

MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”),  a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022. The Company is scheduled to present at the conference at 8:00 am Eastern Time the same day via webcast.

CVRx to Present at the Piper Sandler 34th Annual Healthcare Conference

The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians

CVRx Launches new Barostim NEO2™ Implantable Pulse Generator

MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following upcoming investors conferences on Thursday, November 17, 2022:

CVRx to Attend Upcoming Investor Conferences

CVRx, Inc. (NASDAQ:CVRX ) Q3 2022 Earnings Conference Call November 1, 2022 5:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President and CEO Jared Oasheim - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Alex Nowak - Craig-Hallum Operator Good day and thank you for standing by. Welcome to the CVRx Third Quarter 2022 Earnings Conference Call.

CVRx, Inc. (CVRX) Q3 2022 Earnings Call Transcript

Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year

CVRx Reports Third Quarter 2022 Financial and Operating Results

MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2022 financial and operating results after market close on Tuesday, November 1st, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/8kfcmjvb. To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About CVRx, Inc. CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

News for CVRx Stock (CVRX)